Faricimab, Neovascular Age-Related Macular Degeneration (nAMD), Intravitreal Injections, Best-Corrected Visual Acuity, Phase 3 Trials, Aflibercept, Ocular Adverse Events, Non-Inferiority, Angiopoietin-2, Vascular Endothelial Growth Factor A (VEGF-A), Treatment Regimens, TENAYA, LUCERNE. This evidence concerns the gene ANGPT2 and age-related macular degeneration.